PubRank

Gerold Bepler

Author PubWeight™ 129.92‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007 8.28
2 Non-small cell lung cancer. J Natl Compr Canc Netw 2010 3.93
3 Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006. Arch Intern Med 2008 3.07
4 Racial diversity of actionable mutations in non-small cell lung cancer. J Thorac Oncol 2015 2.80
5 Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. Chest 2004 2.73
6 Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006 2.68
7 Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004 2.54
8 Physician referral for fertility preservation in oncology patients: a national study of practice behaviors. J Clin Oncol 2009 2.31
9 Incorporating genetic susceptibility feedback into a smoking cessation program for African-American smokers with low income. Cancer Epidemiol Biomarkers Prev 2002 2.26
10 Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res 2005 2.19
11 Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable non-small-cell lung cancer. J Clin Oncol 2008 2.18
12 Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 2009 2.13
13 Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol 2008 1.97
14 RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene 2003 1.95
15 ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005 1.93
16 Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 2007 1.91
17 Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 2003 1.88
18 Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol 2010 1.88
19 Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006 1.68
20 Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase. Cancer Res 2006 1.68
21 Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol 2008 1.61
22 Relationship between tumor size and survival among patients with resection of multiple synchronous lung cancers. J Thorac Oncol 2010 1.50
23 Malignant pleural mesothelioma: a comprehensive review. Cancer Control 2006 1.47
24 Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis. Cancer 2011 1.46
25 Proteomic contributions to personalized cancer care. Mol Cell Proteomics 2008 1.46
26 The guinea pig syndrome: improving clinical trial participation among thoracic patients. J Thorac Oncol 2007 1.31
27 Lung cancer. Practice organization. Chest 2003 1.27
28 A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer. J Thorac Oncol 2007 1.25
29 Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer. J Clin Oncol 2004 1.23
30 The feasibility of online genetic testing for lung cancer susceptibility: uptake of a web-based protocol and decision outcomes. Genet Med 2008 1.23
31 Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer. J Thorac Oncol 2011 1.23
32 Responses to online GSTM1 genetic test results among smokers related to patients with lung cancer: a pilot study. Cancer Epidemiol Biomarkers Prev 2009 1.22
33 Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int J Biochem Cell Biol 2007 1.19
34 Persistent smoking after a diagnosis of lung cancer is associated with higher reported pain levels. J Pain 2009 1.18
35 Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. J Clin Oncol 2008 1.17
36 Regular aspirin use and lung cancer risk. BMC Cancer 2002 1.15
37 Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. Cancer 2008 1.15
38 Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells. PLoS One 2012 1.12
39 Obtaining DNA from a geographically dispersed cohort of current and former smokers: use of mail-based mouthwash collection and monetary incentives. Nicotine Tob Res 2004 1.11
40 ID1 facilitates the growth and metastasis of non-small cell lung cancer in response to nicotinic acetylcholine receptor and epidermal growth factor receptor signaling. Mol Cell Biol 2011 1.11
41 Patient-provider communication and perspectives on smoking cessation and relapse in the oncology setting. Patient Educ Couns 2009 1.11
42 Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer. Oncology 2005 1.02
43 Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. Lung Cancer 2004 1.01
44 Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. Clin Cancer Res 2008 1.01
45 EGR1 predicts PTEN and survival in patients with non-small-cell lung cancer. J Clin Oncol 2005 1.01
46 Interpretation of genetic risk feedback among African American smokers with low socioeconomic status. Health Psychol 2004 0.99
47 Retracted A small molecule inhibits Akt through direct binding to Akt and preventing Akt membrane translocation. J Biol Chem 2010 0.98
48 Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older. Cancer 2008 0.98
49 Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells. PLoS One 2012 0.97
50 Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment. Curr Treat Options Oncol 2010 0.96
51 Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab. J Thorac Oncol 2007 0.96
52 Beta-carotene in multivitamins and the possible risk of lung cancer among smokers versus former smokers: a meta-analysis and evaluation of national brands. Cancer 2008 0.95
53 Extracellular signal-regulated kinase (ERK) phosphorylates histone deacetylase 6 (HDAC6) at serine 1035 to stimulate cell migration. J Biol Chem 2013 0.95
54 Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer. Oncoimmunology 2013 0.94
55 Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer. J Thorac Oncol 2010 0.93
56 High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma. Clin Cancer Res 2009 0.90
57 Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 2010 0.90
58 Molecular classification of nonsmall cell lung cancer using a 4-protein quantitative assay. Cancer 2011 0.90
59 Setting the stage for tailored chemotherapy in the management of non-small cell lung cancer. Future Oncol 2008 0.89
60 Phase II study of neoadjuvant chemotherapy with gemcitabine and vinorelbine in resectable non-small cell lung cancer. Chest 2005 0.89
61 Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells. Cancer Biol Ther 2009 0.89
62 Antiapoptotic signaling pathways in non-small-cell lung cancer: biology and therapeutic strategies. Clin Lung Cancer 2004 0.89
63 Modulation of the ribonucleotide reductase M1-gemcitabine interaction in vivo by N-ethylmaleimide. Biochem Biophys Res Commun 2011 0.88
64 Targeted therapy in combination with gemcitabine in non-small cell lung cancer. Semin Oncol 2003 0.88
65 On Bayesian methods of exploring qualitative interactions for targeted treatment. Stat Med 2012 0.88
66 Lung cancer: provoking new concepts, generating novel ideas, and rekindling enthusiasm. Cancer Control 2003 0.88
67 Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma. J Immunother 2013 0.87
68 Ribonucleotide reductase is not limiting for mitochondrial DNA copy number in mice. Nucleic Acids Res 2010 0.87
69 Molecular predictors of chemotherapy response in non-small-cell lung cancer. Expert Rev Anticancer Ther 2007 0.87
70 Prognostic significance of gelsolin expression level and variability in non-small cell lung cancer. Lung Cancer 2004 0.86
71 A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors. Clin Cancer Res 2014 0.86
72 Lung cancer chemoprevention: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest 2007 0.86
73 Modulation of the ribonucleotide reductase-antimetabolite drug interaction in cancer cell lines. J Nucleic Acids 2010 0.86
74 Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II study. J Thorac Oncol 2014 0.84
75 A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy. PLoS One 2013 0.84
76 Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study. Clin Cancer Res 2006 0.84
77 Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients. BJU Int 2010 0.84
78 Fibroblast growth factor receptor 1 amplification in non-small cell lung cancer by quantitative real-time PCR. PLoS One 2013 0.84
79 Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution. Cancer Control 2003 0.82
80 Are we coming full circle for lung cancer screening a second time? Am J Respir Crit Care Med 2009 0.82
81 Crizotinib: an anaplastic lymphoma kinase inhibitor. Future Oncol 2011 0.82
82 Quality of care in non-small-cell lung cancer: findings from 11 oncology practices in Florida. J Oncol Pract 2011 0.81
83 Thymic malignancies. J Natl Compr Canc Netw 2010 0.81
84 Lung cancer patients' decisions about clinical trials and the theory of planned behavior. J Cancer Educ 2011 0.81
85 Non-small cell lung cancer. J Natl Compr Canc Netw 2008 0.81
86 Rupture of a cerebral arteriovenous malformation in a patient treated with bevacizumab. J Thorac Oncol 2009 0.80
87 Choline phosphate cytidylyltransferase-α is a novel antigen detected by the anti-ERCC1 antibody 8F1 with biomarker value in patients with lung and head and neck squamous cell carcinomas. Cancer 2014 0.79
88 Small tumor size and limited smoking history predicts activated epidermal growth factor receptor in early-stage non-small cell lung cancer. Chest 2005 0.79
89 Expression of TGFbeta type-II receptor in association with markers of proliferation and apoptosis in premalignant lung lesions. Cancer 2007 0.78
90 Prognostic significance of expression of p53 oncoprotein in primary (stage I-IIIa) non-small cell lung cancer. Anticancer Res 2003 0.78
91 Protein kinase C-beta gene variants, pathway activation, and enzastaurin activity in lung cancer. Clin Lung Cancer 2010 0.78
92 Parameters for individualizing systemic therapy in non-small cell lung cancer. Drug Resist Updat 2010 0.78
93 Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers. Cancer 2012 0.78
94 Glucocorticoid receptor status is a principal determinant of variability in the sensitivity of non-small-cell lung cancer cells to pemetrexed. J Thorac Oncol 2014 0.78
95 Assessment of the impact of adjunctive proactive telephone counseling to promote smoking cessation among lung cancer patients' social networks. Am J Health Promot 2013 0.77
96 Phase I-II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines. Cancer Chemother Pharmacol 2010 0.77
97 Proactive recruitment of cancer patients' social networks into a smoking cessation trial. Contemp Clin Trials 2011 0.76
98 A mass spectrometry assay to simultaneously analyze ROS1 and RET fusion gene expression in non-small-cell lung cancer. J Thorac Oncol 2015 0.75
99 Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach. Pancreas 2016 0.75
100 Thymidylate synthase 1 (TS1) in-situ protein expression predicts the survival of Ewing/PNET. Fetal Pediatr Pathol 2010 0.75
101 Statins and lung cancer risk. Chest 2007 0.75
102 Reported cessation advice given to African Americans by health care providers in a community health clinic. J Community Health 2002 0.75
103 Re: Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia. J Natl Cancer Inst 2005 0.75
104 Commentary: concomitant chemotherapy and radiation for limited stage small cell lung cancer and benefit of adding additional drug into chemotherapy regimen for advanced non-small cell lung cancer. Cancer Treat Rev 2006 0.75
105 Southern Blotting of genomic DNA from lung and its tumors. Application to analysis of allele loss on chromosome 11p15.5. Methods Mol Med 2003 0.75
106 A small molecule inhibits Akt through direct binding to Akt and preventing Akt membrane translocation. J Biol Chem 2016 0.75
107 Prognostic and predictive markers for personalized adjuvant therapy for non-small-cell lung cancer patients. Future Oncol 2013 0.75
108 Standardizing Assessment of Competences and Competencies of Oncology Nurses Working in Ambulatory Care. J Nurses Prof Dev 2016 0.75
109 Neoadjuvant chemotherapy for resectable non-small-cell lung cancer. Oncology (Williston Park) 2009 0.75